Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cholangiocarcinoma (CCA) is a challenging cancer with limited treatment options.
• Molecular profiling is increasingly important for guiding cancer therapy.
• Targeted therapies represent a paradigm shift towards personalized medicine in oncology.

Purpose of the Study:

• To comprehensively review current targeted therapies for cholangiocarcinoma (CCA).
• To summarize knowledge on molecular pathways and mutations relevant to CCA treatment.
• To recommend targeted treatment options based on molecular profiles and clinical evidence.

Main Methods:

• Systematic literature review of published data, clinical trials, and congress contributions.
• Analysis of palliative, preoperative, and perioperative treatment regimens.
• Evaluation of targeted therapies for specific mutations (IDH, BRAF, NTRK) and molecular alterations (FGFR2 fusion, HER2/neu, MSI, EGFR, VEGF).

Main Results:

• Identified established second-line targeted treatments for IDH-, BRAF-, NTRK-mutated, FGFR2 fusion, HER2/neu-overexpressing, and microsatellite instable cholangiocarcinoma.
• Highlighted EGFR- and VEGF-dependent pathways as potential targets currently under investigation.
• Demonstrated the potential of targeted therapies to improve patient outcomes based on individual tumor molecular characteristics.

Conclusions:

• Targeted therapies are crucial for individualized medicine in cholangiocarcinoma.
• Specific molecular alterations in CCA can be effectively targeted with existing or emerging therapies.
• Personalized treatment strategies based on molecular profiling are essential for improving patient outcomes in CCA.